Biocon Biologics completes integration of Viatris' biosimilar business in 120 countries

The company said over 10 emerging markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris. With the completion of this significant milestone, Biocon Biologics is now a fully integrated ‘lab to market’ biosimilars company committed to serving millions of patients across the globe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H49fyRp
via IFTTT